The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
because we have this incredibly sensitive biomarker that detects whether or not there's a recurrence of frankly when 100 200 cells you know you'll pick up something like that low levels and so we have ways to more aggressively deploy um early Salvage therapies versus kind of upfront so instead of just taking this bazooka approach you can be a sniper
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.